Palliative chemotherapy in advanced bladder cancer

Area of Science:

• Oncology
• Urothelial Carcinomas
• Cancer Chemotherapy

Background:

• Transitional cell carcinoma of the urothelium is a chemosensitive cancer.
• Current standard chemotherapy (methotrexate/vinblastine/doxorubicin/cisplatin) offers modest survival but has significant toxicity.
• Dose escalation of the standard regimen has not improved efficacy.

Purpose of the Study:

• To review the efficacy and toxicity of current chemotherapy for advanced urothelial carcinoma.
• To explore novel chemotherapeutic agents and combination regimens for improved outcomes.
• To identify potential treatments for earlier stages of bladder cancer with curative intent.

Main Methods:

• Review of phase III clinical trials and published data on chemotherapy for advanced urothelial carcinoma.
• Analysis of response rates and survival durations associated with standard and novel regimens.
• Evaluation of the role of new agents like paclitaxel, gallium nitrate, ifosfamide, and gemcitabine.

Main Results:

• The standard four-drug regimen yields response rates of 35-45% and a median survival of 12 months.
• Attempts to reduce toxicity with growth factors were successful, but dose escalation failed to increase efficacy.
• Paclitaxel has shown significant activity as a single agent in untreated advanced bladder cancer patients.

Conclusions:

• There is a need for alternative combination chemotherapy regimens with improved efficacy and manageable toxicity.
• Novel agents like paclitaxel are promising for treating advanced urothelial carcinoma.
• Ongoing research aims to develop superior regimens for advanced and earlier-stage bladder cancer.